Group | Malaria Vaccines

The RTS,S vaccine candidate produced by GlaxoSmithKline (GSK) Biologicals was tested in a Phase 2 trial completed by Ifakara Health Institute (IHI) and Swiss TPH in 2008. That trial showed that co-administration with EPI-vaccines does not affect the safety and immunogenicity of malaria and EPI vaccines and results in substantial and consistent protection in infants.

A recently completed Phase 3 trial undertaken at the IHI’s Bagamoyo branch, as well as in 10 other African centres and including 16'000 infants and small children, demonstrated a 56% protection rate against malaria episodes and a 34% reduction in severe malaria incidence. Our group is also involved in a number of other trials of vaccine candidates, as well as in the immunological study of the vaccine’s responses.

Marcel Tanner

Marcel Tanner, Professor, PhD, Epidemiologist, MPH

AlKhaldi M et al. Mapping stakeholders of the Palestinian Health Research System: a qualitative study. East Mediterr Health J. 2020;26(3):340-348. DOI: 10.26719/emhj.19.016

Billingsley P.F et al. The equatoguinean malaria vaccine initiative: from the launching of a clinical research platform to malaria elimination planning in Central West Africa. Am J Trop Med Hyg. 2020(in press). DOI: 10.4269/ajtmh.19-0966

Camponovo F et al. Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults. Elife. 2020;9:e53080. DOI: 10.7554/eLife.53080

Ehrenberg J.P, Zhou X.N, Fontes G, Rocha E.M.M, Tanner M, Utzinger J. Strategies supporting the prevention and control of neglected tropical diseases during and beyond the COVID-19 pandemic. Infect Dis Poverty. 2020;9:86. DOI: 10.1186/s40249-020-00701-7

Guirou E.A et al. Molecular malaria surveillance using a novel protocol for extraction and analysis of nucleic acids retained on used rapid diagnostic tests. Sci Rep. 2020;10:12305. DOI: 10.1101/2020.02.17.20023960